These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 21556811)

  • 1. Development of genetically engineered CD4+ and CD8+ T cells expressing TCRs specific for a M. tuberculosis 38-kDa antigen.
    Luo W; Zhang XB; Huang YT; Hao PP; Jiang ZM; Wen Q; Zhou MQ; Jin Q; Ma L
    J Mol Med (Berl); 2011 Sep; 89(9):903-13. PubMed ID: 21556811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of genetically engineered iNKT cells expressing TCRs specific for the M. tuberculosis 38-kDa antigen.
    Jiang ZM; Luo W; Wen Q; Liu SD; Hao PP; Zhou CY; Zhou MQ; Ma L
    J Transl Med; 2015 May; 13():141. PubMed ID: 25943357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.
    Chhabra A; Yang L; Wang P; Comin-Anduix B; Das R; Chakraborty NG; Ray S; Mehrotra S; Yang H; Hardee CL; Hollis R; Dorsky DI; Koya R; Kohn DB; Ribas A; Economou JS; Baltimore D; Mukherji B
    J Immunol; 2008 Jul; 181(2):1063-70. PubMed ID: 18606658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
    Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
    J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited T cell receptor repertoire diversity in tuberculosis patients correlates with clinical severity.
    Luo W; Su J; Zhang XB; Yang Z; Zhou MQ; Jiang ZM; Hao PP; Liu SD; Wen Q; Jin Q; Ma L
    PLoS One; 2012; 7(10):e48117. PubMed ID: 23110186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leucocyte antigen class I-redirected anti-tumour CD4
    Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
    Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
    Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
    Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
    Engels B; Chervin AS; Sant AJ; Kranz DM; Schreiber H
    Mol Ther; 2012 Mar; 20(3):652-60. PubMed ID: 22233579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human CD8(+) T cells transduced with an additional receptor bispecific for both Mycobacterium tuberculosis and HIV-1 recognize both epitopes.
    Zhou CY; Wen Q; Chen XJ; Wang RN; He WT; Zhang SM; Du XL; Ma L
    J Cell Mol Med; 2016 Oct; 20(10):1984-98. PubMed ID: 27113787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
    Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells.
    Lee MN; Meyerson M
    Sci Immunol; 2021 Jan; 6(55):. PubMed ID: 33483338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
    Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
    PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
    Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
    J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles.
    Shams H; Klucar P; Weis SE; Lalvani A; Moonan PK; Safi H; Wizel B; Ewer K; Nepom GT; Lewinsohn DM; Andersen P; Barnes PF
    J Immunol; 2004 Aug; 173(3):1966-77. PubMed ID: 15265931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.
    Soto CM; Stone JD; Chervin AS; Engels B; Schreiber H; Roy EJ; Kranz DM
    Cancer Immunol Immunother; 2013 Feb; 62(2):359-69. PubMed ID: 22926060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
    Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
    Front Immunol; 2019; 10():2076. PubMed ID: 31552033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.